ArticleACS omega2025
Curcuminoid-Linked Lemon-Derived Carbon Dots for pH-Triggered Drug Release.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Synthesis of curcumin-derived carbon dots with dual antimicrobial and osteogenic properties for enhanced bone regeneration.Frontiers in cell and developmental biology · 2026Article
- Green carbon dots in the era of AI: sustainable synthesis, intelligent drug delivery, advanced diagnostics, and bioimaging.Turkish journal of biology = Turk biyoloji dergisi · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The supramolecular architectures were designed from lemon-derived carbon dots (LCDs) and curcuminoids. Curcuminoids were used to link the carbon dots to create a supramolecular architecture via an ester linkage. The optical characteristics of curcuminoid-linked lemon carbon dots (CL-LCDs) demonstrated that CL-LCDs-1 can be used for bioimaging applications among all of the LCD derivatives. The HR-TEM and FEG-SEM images showed that the size of all CL-LCD derivatives is nearly 10 nm, which is ideal for the development of effective drug delivery systems. The CL-LCDs were used to encapsulate the anticancer drug methotrexate, which demonstrated a sustained drug release profile under pH stimulus. CL-LCDs-3 exhibited a 27.50% cumulative release at pH 5.5 after 7 days. At pH 7.4, CL-LCDs-3 showed a 19.73% cumulative drug release. MTX-loaded CL-LCDs-1 showed the best anticancer activity against HeLa cells, and the photoluminescence was recovered after the drug release, showing its promising application in the field of tumor imaging.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.